e7820
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT00078637)
Timeline
Indications
Mechanism of action
- Integrin alpha-2INHIBITOR
ITGA2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e7820
- e7820
- e7820
- n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05024994 | Phase 2 | Aug 13, 2021 | Eisai, Memorial Sloan-Kettering Cancer Center |
| NCT01347645 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2011 | Eisai, IQVIA, PharmaBio Development Inc. |
| NCT01773421 | Phase 1 | Jul 8, 2011 | Eisai |
| NCT01133990 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2010 | Eisai, IQVIA, PharmaBio Development Inc. |
| NCT00309179 | Phase 2 | Sep 1, 2007 | Eisai |
| NCT00078637 | Phase 1 | Jan 1, 2004 | Eisai |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 6 | 5 | 2 | 2004 |
| IQVIA | For profit | 2 | 0 | 1 | 2010 |
| PharmaBio Development Inc. | For profit | 2 | 0 | 1 | 2010 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1